Diffuse Alveolar Hemorrhage

dc.contributor.authorDesai, Hem
dc.contributor.authorSmith, Joshua
dc.contributor.authorWilliams, Mark Daren
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2020-07-02T16:59:17Z
dc.date.available2020-07-02T16:59:17Z
dc.date.issued2019-07-24
dc.descriptionThis article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
dc.description.abstractDiffuse alveolar hemorrhage[DAH] is a serious condition that can be life threatening. It can be caused by a constellation of disorders which presents with hemoptysis, anemia, and diffuse alveolar infiltrates. Respiratory failure from DAH can be so severe that it has been called an ARDS mimic/imitator. Early recognition is crucial because prompt diagnosis and treatment are required for survival. DAH should be distinguished from other causes of pulmonary hemorrhage caused by localized pulmonary abnormalities and the bronchial circulation. Early bronchoscopy with bronchoalveolar lavage (BAL) is generally required to confirm the diagnosis of DAH and rule out infection. Progressively bloody bronchoalveolar lavage samples can distinguish DAH. Systemic vasculitis is one of the most common causes of DAH and can be pathologically defined by the presence of cellular inflammation, vessel destruction, tissue necrosis, and eventually, organ dysfunction. Corticosteroids and immunosuppressive agents remain the gold standard for the treatment. The following case illustrates a patient who was dependent on dialysis, then presented with hemoptysis. Bronchoscopy demonstrated progressively bloody bronchoalveolar lavage samples consistent with diffuse alveolar hemorrhage. Serologic testing was consistent with microscopic polyangiitis. The patient experienced a clinical remission with cyclophosphamide and corticosteroids.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationDesai, H., Smith, J., & Williams, M. D. (2019). Diffuse Alveolar Hemorrhage. Evidence-Based Critical Care: A Case Study Approach, 253–257. https://doi.org/10.1007/978-3-030-26710-0_33en_US
dc.identifier.urihttps://hdl.handle.net/1805/23157
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.relation.isversionof10.1007/978-3-030-26710-0_33en_US
dc.relation.journalEvidence-Based Critical Careen_US
dc.rightsThis article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
dc.sourcePMCen_US
dc.subjectDiffuse alveolar hemorrhageen_US
dc.subjectMicroscopic Polyangiitisen_US
dc.subjectGlomerulonephritisen_US
dc.subjectHemoptysisen_US
dc.subjectRenal failureen_US
dc.subjectVasculitisen_US
dc.subjectAntineutrophil cytoplasmic antibodyen_US
dc.subjectPulmonary-renal syndromeen_US
dc.subjectCytoxanen_US
dc.subjectRituximaben_US
dc.titleDiffuse Alveolar Hemorrhageen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
978-3-030-26710-0_Chapter_33.pdf
Size:
436.81 KB
Format:
Adobe Portable Document Format
Description:
Book chapter
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: